Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 3, 2013, Pages 274-277

  Boivin, Andrée Anne ^a   Cardinal, Héloïse ^a   Barama, Azemi ^a   Naud, Judith ^b   Pichette, Vincent ^b   Hébert, Marie Josée ^a   Roger, Michel ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Drug level; Genetic polymorphisms; Renal transplants; SLCO1B3; Tacrolimus

Indexed keywords

OATP1B3 PROTEIN; ORGANIC ANION TRANSPORTER 1; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANADA; CAUCASIAN; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG TRANSPORT; FEMALE; GENE; GENE MUTATION; GENETIC RISK; GENETIC VARIABILITY; GRAFT RECIPIENT; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; KIDNEY TRANSPLANTATION; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SLCO1B3 GENE; WILD TYPE;

EID: 84879373567     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-SH-093     Document Type: Article

References (25)

1. Ekberg, H.: Calcineurin inhibitor sparing in renal transplantation. Transplantation, 86: 761-767 (2008).
2. Solez, K., Vincenti, F. and Filo, R. S.: Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation, 66: 1736-1740 (1998).
3. Undre, N. A., van Hooff, J., Christiaans, M., Vanrenterghem, Y., Donck, J., Heeman, U., Kohnle, M., Zanker, B., Land, W., Morales, J. M., Andrés, A., Schäfer, A. and Stevenson, P.: Low systemic exposure to tacrolimus correlates with acute rejection. Transplant. Proc., 31: 296-298 (1999).
4. Evans, W. E. and McLeod, H. L.: Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med., 348: 538-549 (2003).
5. Roy, J. N., Barama, A., Poirier, C., Vinet, B. and Roger, M.: Cyp3A4, Cyp3A5, MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet. Genomics, 16: 659-665 (2006).
6. Anglicheau, D., Legendre, C., Beaune, P. and Thervet, E.: Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics, 8: 835-849 (2007).
7. Huang, Y., Penchala, S., Pham, A. N. and Wang, J.: Genetic variations and gene expression of transporters in drug disposition and response. Expert Opin. Drug Metab. Toxicol., 4: 237-254 (2008).
8. Mikkaichi, T., Suzuki, T., Tanemoto, M., Ito, S. and Abe, T.: The organic anion transporter (OATP) family. Drug Metab. Pharmacokinet., 19: 171-179 (2004).
9. Funk, C.: The role of hepatic transporters in drug elimination. Expert Opin. Drug Metab. Toxicol., 4: 363-379 (2008).
10. Hagenbuch, B. and Meier, P. J.: Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch., 447: 653-665 (2004).
11. Leuthold, S., Hagenbuch, B., Mohebbi, N., Wagner, C. A., Meier, P. J. and Stieger, B.: Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am. J. Physiol. Cell Physiol., 296: C570-C582 (2009).
12. Abe, T., Unno, M., Onogawa, T., Tokui, T., Kondo, T. N., Nakagomi, R., Adachi, H., Fujiwara, K., Okabe, M., Suzuki, T., Nunoki, K., Sato, E., Kakyo, M., Nishio, T., Sugita, J., Asano, N., Tanemoto, M., Seki, M., Date, F., Ono, K., Kondo, Y., Shiiba, K., Suzuki, M., Ohtani, H., Shimosegawa, T., Iinuma, K., Nagura, H., Ito, S. and Matsuno, S.: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology, 120: 1689-1699 (2001).
13. Hamada, A., Sissung, T., Price, D. K., Danesi, R., Chau, C. H., Sharifi, N., Venzon, D., Maeda, K., Nagao, K., Sparreboom, A., Mitsuya, H., Dahut, W. L. and Figg, W. D.: Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin. Cancer Res., 14: 3312-3318 (2008).
14. Tsujimoto, M., Hirata, S., Dan, Y., Ohtani, H. and Sawada, Y.: Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab. Pharmacokinet., 21: 165-169 (2006).
15. Smith, N. F., Marsh, S., Scott-Horton, T. J., Hamanda, H., Mielke, S., Mross, K., Figg, W. D., Verweij, J., McLeod, H. L. and Sparreboom, A.: Variants in the SLCO1B3 gene: Interethnic distribution and association with paclitaxel pharmacokinetics. Clin. Pharmacol. Ther., 81: 76-82 (2007).
16. Boivin, A. A., Cardinal, H., Barama, A., Pichette, V., Hébert, M. J. and Roger, M.: Organic anion transporting polypeptide (OATP) 1B1 and OATP1B3: Genetic variability and haplotype analysis in white Canadians. Drug Metab. Pharmacokinet., 25: 508-515 (2010).
17. Picard, N., Yee, S. W., Woillard, J. B., Lebranchu, Y., Le Meur, Y., Giacomini, K. M. and Marquet, P.: The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin. Pharmacol. Ther., 87: 100-108 (2010).
18. Fehrenbach, T., Cui, Y., Faulstich, H. and Keppler, D.: Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch. Pharmacol., 368: 415-420 (2003).
19. Elens, L., Capron, A., Van Kerckhove, V., Lerut, J., Mourad, M., Lison, D., Wallemacq, P. and Haufroid, V.: 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet. Genomics, 17: 873-883 (2007).
20. König, J., Cui, T., Nies, A. T. and Keppler, D.: Localization and genomic organization of new hepatocellulaur organic anion transporting polypeptide. J. Biol. Chem., 275: 23161-23168 (2000).
21. Racusen, L. C., Solez, K., Colvin, R. B., Bonsib, S. M., Castro, M. C., Cavallo, T., Croker, B. P., Demetris, A. J., Drachenberg, C. B., Fogo, A. B., Furness, P., Gaber, L. W., Gibson, I. W., Glotz, D., Goldberg, J. C., Grande, J., Halloran, P. F., Hansen, H. E., Hartley, B., Hayry, P. J., Hill, C. M., Hoffman, E. O., Hunsicker, L. G., Lindblad, A. S. and Yamaguchi, Y.: The Banff 97 working classification of renal allograft pathology. Kidney Int., 55: 713-723 (1999).
22. Sissung, T. M., Baum, C. E., Kirkland, C. T., Gao, R., Gardner, E. R. and Figg, W. D.: Pharmacogenetics of membrane transporters: an update on current approaches. Mol. Biotechnol., 44: 152-167 (2010).
23. Tamai, I., Nezu, J., Uchino, H., Sai, Y., Oku, A., Shimane, M. and Tsuji, A.: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun., 273: 251-260 (2000).
24. König, J., Seithel, A., Gradhand, U. and Fromm, M. F.: Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol., 372: 432-443 (2006).
25. Letschert, K., Keppler, D. and Konig, J.: Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics, 14: 441-452 (2004).